CG Oncology, Inc. Common stock - Asset Resilience Ratio
CG Oncology, Inc. Common stock (CGON) has an Asset Resilience Ratio of 89.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CG Oncology, Inc. Common stock's Asset Resilience Ratio has changed over time. See CG Oncology, Inc. Common stock (CGON) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down CG Oncology, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of CG Oncology, Inc. Common stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $709.66 Million | 89.65% |
| Total Liquid Assets | $709.66 Million | 89.65% |
Asset Resilience Insights
- Very High Liquidity: CG Oncology, Inc. Common stock maintains exceptional liquid asset reserves at 89.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CG Oncology, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare CG Oncology, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CG Oncology, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 89.65% | $709.66 Million | $791.59 Million | +25.40pp |
| 2024-12-31 | 64.25% | $484.93 Million | $754.80 Million | -25.77pp |
| 2023-12-31 | 90.02% | $179.41 Million | $199.30 Million | +52.56pp |
| 2022-12-31 | 37.45% | $55.34 Million | $147.75 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $58.69 Million | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more